Since 2014
The impact of biomedical innovation on longevity and health
Nordic Journal of Health Economics
View Archive Info| Field | Value | |
| Title |
The impact of biomedical innovation on longevity and health
|
|
| Creator |
Lichtenberg, Frank R; Columbia University, New York, United States; National Bureau of Economic Research, Cambridge, United States; and CESifo, Munich, Germany
|
|
| Subject |
—
longevity, health, biomedical, research, innovation, pharmaceutical C2, I12, J11, L650, O330 |
|
| Description |
Many authors have expressed the view that a substantial portion of recent gains in longevity and health is due to biomedical research and innovation. This article describes the methodologies and findings of a number of studies based on observational data that have sought to measure the impact of biomedical innovation on the longevity and health of Americans and other populations during recent decades. Most of these studies have examined the impact of innovation in pharmaceuticals, the most research-intensive medical good or service. Two measures of medical innovation that have been used are the mean vintage of the medical goods or procedures used by an individual or population, and the number of distinct products (e.g. drugs) available for treating a condition. Longevity (e.g. time till death) is the health outcome that has been analyzed the most, but several studies have studied the impact of medical (i.e. pharmaceutical) innovation on the ability of people to work or engage in activities of daily living. Some studies have been based on cross-sectional patient-level data. Others have been based on longitudinal, region-level data; they have investigated whether regions (e.g. states) undergoing more rapid medical innovation have exhibited larger improvements in health. And some studies have been based on longitudinal, disease-level data; they have investigated whether the medical conditions undergoing more rapid innovation have exhibited larger gains in health outcomes. Innovation related to some specific major diseases (e.g. cardiovascular disease and cancer) has been investigated, but the overall impact of innovation related to other major diseases (e.g. diabetes) has not.These studies provide considerable support for the hypothesis that a substantial portion of recent gains in longevity and health is due to biomedical research and innovation. It would be desirable to apply these methods to data from developing countries.
|
|
| Publisher |
University of Oslo
|
|
| Contributor |
—
|
|
| Date |
2015-03-09
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — |
|
| Format |
application/pdf
|
|
| Identifier |
https://www.journals.uio.no/index.php/NJHE/article/view/1290
10.5617/njhe.1290 |
|
| Source |
Nordic Journal of Health Economics; Vol 5, No 1 (2017): Special issue: The value of new technology; pp. 45-57
1892-9710 1892-9729 |
|
| Language |
eng
|
|
| Relation |
https://www.journals.uio.no/index.php/NJHE/article/view/1290/1177
|
|
| Rights |
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
|
|